Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

It is unclear whether levels of high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I (apoA-I) remain inversely associated with cardiovascular risk among patients who achieve very low levels of low-density lipoprotein cholesterol on statin therapy. It is also unknown whether a rise in HDL-C or apoA-I after initiation of statin therapy is associated with a reduced cardiovascular risk.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Circulation

Title: Circulation

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1524-4539

ISSN (Print): 0009-7322

Publication date (Electronic): Oct 01 2013

Volume: 128

Issue: 14

Affiliations

[1 ] Departments of Cardiology (S.M.B.) and Vascular Medicine (B.J.A., G.K.H., J.J.P.K.), Academic Medical Center, Amsterdam, The Netherlands; Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Boston, MA (S.M., P.M.R.); Center of Preventive Medicine, Oslo University Hospital, Ulleval and University of Oslo, Norway (T.R.P.); State University of New York Health Science Center, Brooklyn, NY (J.C.L.); Rosalind Franklin University of Medicine and Science, North Chicago, IL (K.M.A.W.); Department of Neurology and Stroke Center, Bichat University Hospital, Paris, France (P.A.); Global Pharmaceuticals Pfizer, New York, NY (D.A.D.); Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (A.M.T.); Department of Biochemistry and Lipid Clinic, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia (D.R.S.); NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia (A.K.); Medical Research Institute, University of Dundee, Dundee, United Kingdom (H.M.C.); Centre for Diabetes, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom (G.A.H.); Department of Medicine, Royal Free and University College Medical School, London, United Kingdom (D.J.B.); School of Biomedicine, University of Manchester, Manchester, United Kingdom (P.N.D.); Touro University, Mare Island, CA (M.B.C.); Department of Medicine, University of Texas Health Science Center, and VERDICT, South Texas Veterans Health Care System, San Antonio, TX (J.R.D.); and Weill Cornell Medical College, New York, NY (A.M.G.).

Article

Mid ID: NIHMS517681 Publisher Item ID: CIRCULATIONAHA.113.002670

DOI: 10.1161/CIRCULATIONAHA.113.002670

PMC ID: 3807966

PubMed ID: 23965489

SO-VID: fa8f16cb-3caa-427a-b128-0b5e949d93dd

History

Keywords: apolipoproteins,cardiovascular diseases,high-density lipoprotein cholesterol,meta-analysis

Data availability:

Keywords: apolipoproteins, cardiovascular diseases, high-density lipoprotein cholesterol, meta-analysis

Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

Read this article at

Abstract

Related collections

Cardiovascular Innovations and Applications

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 365

Cited by 68